Sanjay Aggarwal, MD
Internal Medicine · New Haven, CTNPI 1912927658
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $39,900 of the $53,565 with a category attached, or 74.5%. Kadmon Corporation LLC accounts for 74.5% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2020 at $38,650 and has fallen 95.6% since, to $1,691 in 2025. Among internal medicine clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 612 payments — averaging $87.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kadmon Corporation LLC$40K
- AbbVie$2K
- AstraZeneca$2K
- GSK$2K
- Boehringer Ingelheim$1K
- Lilly USA, LLC$714
- plus $6K from 39 others
Across 1 payment — averaging $4600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$5K
What the payments were for
- Consulting fees$39,90074%
- Food & beverage$13,64625%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,565 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $20,258 |
| OzempicSemaglutide | 16 | $17,899 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 72 | $11,723 |
| FarxigaDapagliflozin Propanediol | 25 | $11,495 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $11,244 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 12 | $9,908 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $6,881 |
| SantylCollagenase Clostridium Hist. | 18 | $6,059 |
| MyrbetriqMirabegron | 22 | $5,737 |
| XareltoRivaroxaban | 19 | $5,327 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 11 | $2,383 |
| Lidocaine | 23 | $2,248 |
| Midodrine Hcl | 13 | $2,247 |
| Atorvastatin Calcium | 121 | $1,667 |
| Mirtazapine | 37 | $1,556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $616 | $20,25856 claims |
| Novo NordiskOzempic | $516 | $17,89916 claims |
| GSKTrelegy Ellipta, Shingrix | $1,713 | $13,62826 claims |
| AstraZenecaFarxiga | $1,969 | $11,49525 claims |
| Orexo US, Inc.Zubsolv | $225 | $9,90812 claims |
| Indivior Inc.Suboxone | $615 | $6,88113 claims |
| Astellas Pharma US IncMyrbetriq | $192 | $5,73722 claims |
| Johnson & JohnsonXarelto | $67 | $5,32719 claims |
| Almatica Pharma LLCSertraline Hcl | $19 | $44037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in New Haven
- Nancy BrownNew Haven$1.6M
- Richard LiftonNew Haven$160K
- Wayne WarrenNew Haven$127K
- Marcella SmithNew Haven$66K
- Bubu BaniniNew Haven$39K
- Sandra SpringerNew Haven$39K
- Karen WangNew Haven$38K
- Michael SchilskyNew Haven$36K
- Kenechukwu MezueNew Haven$33K
- Yevgeniya FosterNew Haven$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.